← All trials
NCT02175225
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2014
- Primary completion
- Dec 1, 2017
- Completion date
- Aug 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 294
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- University of PennsylvaniaCollaborator
- Johns Hopkins UniversityCollaborator
- Duke UniversityCollaborator
- University of FloridaCollaborator
- Ohio State UniversityCollaborator
- University of California, San FranciscoCollaborator
- Oregon Health and Science UniversityCollaborator
- University of IowaCollaborator
- Rhode Island HospitalCollaborator
- Stanford UniversityCollaborator
- University of WashingtonCollaborator
- University of CalgaryCollaborator
- Hopital de l'Enfant-JesusCollaborator
- University of AlbertaCollaborator
- Columbia UniversityCollaborator
- Loyola UniversityCollaborator
- Harvard UniversityCollaborator
- Rush UniversityCollaborator
- University of Texas at HoustonCollaborator
- Case Western Reserve UniversityCollaborator
- University of ArizonaCollaborator
- University of MassachusettsCollaborator
- University of North Carolina at Chapel HillCollaborator
- Medical University of South CarolinaCollaborator
- New York UniversityCollaborator
- Yale UniversityCollaborator
- Cornell UniversityCollaborator
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityStudy chair
- Henry Ford Health SystemCollaborator
- Icahn School of Medicine at Mount SinaiCollaborator
- University of ConnecticutCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.